TEVA is one of the most-affected companies from the patent cliff and is struggling to replenish its patent portfolio. In its recent mid-December investor’s conference, the company CEO stressed driving growth by any means necessary. The company refused to increase its yield and stressed reinvestment into new drug candidates and new uses for existing candidates.
Interesting. But TEVA is notorious after-market/generic drug maker from Israel, who lobbied hard to shorten the patent period for new drugs as part of Obamacare.
... Anyway, pharmas will only invest in new drugs if they have proved effective and safe ... or to put it in Jock's words - they "are very data driven". if you do not have statistically significant data to p,rove effectiveness and safety, don't even bother seeking a partner. Jock and CAPS learned the hard way the meaning of "statistically significant" in the bio-industry during the AZX-100 and TP-508 disasters, all at shareholder's expense of course.